MV
Mala Verma
About Mala Verma
Data last updated:
Mala Verma is a Director at Callisto Pharmaceuticals Private Limited (since 2009), Director at Nexansa Technologies Private Limited (since 2026) and Director at Priaan Consulting & Solutions Private Limited (since 2022). The companies operate in Trading and Home Appliances. The largest current company by reported revenue is Callisto Pharmaceuticals Private Limited at ₹48 Lakh (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 10 Sep 2009 | 2009 | ₹48 Lakh (FY 2025) | Active | |
| Director | 10 Aug 2026 | 2026 | Active | ||
| Director | 21 Oct 2022 | 2022 | Active |
Board colleagues of Mala Verma
| Name | DIN | Company | Designation |
|---|---|---|---|
| Rajesh Sinha | 01831266 | Callisto Pharmaceuticals Private Limited | Director |
| Prashant Verma | 05222071 | Nexansa Technologies Private Limited , Priaan Consulting & Solutions Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Mala Verma
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mala Verma
Mala Verma currently holds 3 directorships: Callisto Pharmaceuticals Private Limited (Director, since 10 Sep 2009, revenue ₹48 Lakh (FY 2025)); Nexansa Technologies Private Limited (Director, since 10 Aug 2026); Priaan Consulting & Solutions Private Limited (Director, since 21 Oct 2022).
Mala Verma was first appointed on 10 Sep 2009 as Director at Callisto Pharmaceuticals Private Limited. The most recent appointment on record is 10 Aug 2026 at Nexansa Technologies Private Limited.
The current boards of Mala Verma's companies include Rajesh Sinha (Callisto Pharmaceuticals Private Limited), Prashant Verma (Nexansa Technologies Private Limited).